BRII-B (02137.HK) announced new live virus data confirming that the amubarvimab/ romlusevimab combination, a long-acting COVID-19 monoclonal antibody therapy, retains
neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.
The U.S. Food and Drug Administration is currently reviewing the Company's Emergency Use Authorization application for the amubarvimab/ romlusevimab combination.
neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.
The U.S. Food and Drug Administration is currently reviewing the Company's Emergency Use Authorization application for the amubarvimab/ romlusevimab combination.